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Abstract: To produce fish of a high quality that are rich in omega-3 fatty acids (n-3 FA) and
simultaneously generate more sustainable aquaculture, the combined use of phytochemicals and
vegetable oils in fish feed seems to be a promising approach. Resveratrol (RV) potentially induces
endogenous fatty acid synthesis, resulting in elevated n-3 FA levels in fish. RV putatively influences
∆6-desaturase, the key enzyme in FA metabolism, and serves as a ligand for PPARα, a transcription
factor regulating β-oxidation. Rainbow trout (36.35± 0.03 g) were randomly allocated into six groups
and fed diets with reduced fish oil levels (F4 = 4%, F2 = 2% and F0 = 0% of dry matter) supplemented
with 0.3% (w/w) RV (F4 + RV, F2 + RV and F0 + RV). RV significantly affected FA composition in liver
tissue and whole fish homogenates. 20:5n-3 (EPA) and 22:6n-3 (DHA) were significantly increased
whereas precursor FA were diminished in fish fed the F2 + RV and F0 + RV diets when compared to
F4 + RV and F0. RV significantly elevated ∆6-desaturase protein levels in the livers of F0 + RV fed
animals. Hepatic mRNA expression of ∆6-desaturase, PPARα, and its target genes were affected by
the dietary fish oil level and not by dietary RV. The results of this study indicated a potential benefit
of supplementing RV in fish oil deprived diets elevating n-3 FA levels in rainbow trout.
Keywords: CPT1; fish oil replacement; hepatic fatty acid synthesis; long chain polyunsaturated fatty
acids; mRNA expression; phytochemical; PPARα
1. Introduction
Seafood, fish, and fish products are important dietary sources of health beneficial omega-3
fatty acids (n-3 FA) and thus important in human nutrition [1–4]. In particular the n-3 long chain
poly-unsaturated FA (LC-PUFA) eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA,
22:6n-3) may mediate health benefits and are of increasingly recognized importance [5–8]. For the
production of healthy fish rich in these n-3 LC-PUFAs, the nutrition of the fish itself plays a crucial
role [9]. On the one hand, marine ingredients in fish diets have a positive effect on fish health, survival
and growth rates [10,11]. On the other hand, the shortage of marine resources for fish meal and fish oil
production and the demand for sustainable aquaculture requires the use of alternative raw materials.
These are often plant based and differ in nutritional value, digestibility and nutrient availability in
comparison to marine derived feed ingredients. When dietary fish oil is replaced by plant oils, the
resulting FA composition in fish often changes to a profile rather poor in n-3 FA, thus making them
less valuable for human nutrition [12–17]. Considerable effort has been made in the past decade to
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counteract this trend where various approaches have been considered including the use of n-3 FA rich
finishing diets after feeding plant based diets [14,18], the inclusion of microalgae rich in n-3 FA [19–21],
the use of n-3 enriched oil from genetically modified oilseeds [22], and the application of secondary
plant compounds to alter endogenous n-3 FA synthesis [23,24], amongst others.
Fresh water fish have the ability to synthetize EPA and DHA [25–27] from the essential precursor
n-3 PUFA alpha-linolenic acid (ALA, 18:3n-3). The hepatic FA conversion from ALA to EPA and further
to DHA takes place in the endoplasmic reticulum and comprises several elongation and desaturation
steps, followed by a final β-oxidation in the peroxisome [26,28] (Figure 1). The LC-PUFA synthesis is
a complex process requiring different enzymes, transcription factors and various target genes. The
rate-limiting key enzyme of this process is ∆6-desaturase (∆6-D), which introduces an additional
double bond in ALA and initiates the LC-PUFA synthesis [29]. Aside from the ∆6-D and ∆5-desaturase
(∆5-D), the nuclear hormone receptors peroxisome proliferator-activated receptors (PPARs) and its
target genes including carnitine palmitoyl transferase 1 (CPT1), sterol regulatory element binding
protein 1 (SREBP-1), and acyl-CoA oxidase 1 (acox1) are centrally involved in LC-PUFA synthesis and
regulation of this process (Figure 1).
In rainbow trout (Oncorhynchus mykiss), the endogenous FA synthesis may last 2–4 weeks to
convert dietary ALA into EPA and DHA and contributes only to a small extend to n-3 LC-PUFA
tissue levels [30]. This indicates that LC-PUFAs are putatively essential for rainbow trout and should
be supplied via dietary intake. Under experimental conditions, it is feasible to reduce marine feed
ingredients (and thus dietary EPA and DHA levels) without compromising fish performance [31,32].
However, a more recent study showed that a complete reduction of marine feed ingredients over a
whole production cycle in rainbow trout was possible [33]. However, the vegetable diet significantly
negatively affected growth and the n-3 FA content of fish (carcass n-3 PUFAs in polar lipids reduced
from 45.1% to 32.1% FAMEs and in neutral lipids from 31.4% to 14.3% FAMEs) [33]. Thus, in
commercial scale production, trout diets still need to meet minimum requirements for essential
fatty acids (EPA + DHA: 0.4–0.5% DM of diet and ALA: 0.7–1.0% DM of diet [34]) to ensure an end
product with adequate amounts of n-3 LC-PUFA. According to several studies, the n-3 LC-PUFA
content of farmed and wild salmonids varies largely depending on commercial feed and/or region
(rainbow trout farmed versus wild: 931 and 268 mg/100 g, respectively [35]; Atlantic salmon farmed
vs. wild: >1400 and <900 mg/100 g, respectively [17]). In farmed salmonids, amounts of EPA and DHA
are decreasing parallel to increasing use of dietary vegetable oils leading to increased portion sizes to
meet recommended dietary amounts of EPA + DHA of 200–500 mg/day [17,36]. For the production of
healthy fish with sufficient amounts of EPA and DHA and a reduction of marine dietary resources,
secondary plant compounds that may have the ability to modify endogenous FA synthesis in vivo
should be considered. Genistein and lipoic acid [37], or a mixture of episesamin/sesamin [37,38] were
shown to increase the expression levels of genes encoding proteins involved in FA synthesis in salmon
hepatocytes in vitro (for example ∆6-D, PPARα and CPT1). Further, Trattner et al. [23] enhanced EPA
and DHA levels in rainbow trout in vivo with feeding diets containing a sesamin/episesamin mixture.
EPA was elevated significantly from 5.2% to 5.6% FAMEs and DHA from 38.6% to 43.7% FAMEs when
rainbow trout were fed sesamin/episesamin-supplemented diets [23].
In this study, the phytochemical resveratrol (RV) was investigated for its potential to
induce LC-PUFA synthesis in rainbow trout. RV is a stilbene found in different plants, mainly
grapevine, with potentially health-beneficial and, amongst others, anti-oxidant and anti-inflammatory
properties [39–41]. Over thirty years ago, RV was proven to modulate lipid metabolism (reduced
lipogenesis and increased lipolysis) in rats [42,43]. RV up-regulated PPARα in a neuron model [44]
and furthermore was described as PPAR activator in several in vitro and in vivo studies, as reviewed
by Nakata et al. [45]. Two studies, both combining in vitro cell culture assays with in vivo experiments
in mice, suggested that RV activated PPARα [46,47]. RV putatively increased elongase and desaturase
activities (∆6-D and ∆5-D) resulting in elevated DHA levels [48] (Figure 1). Recently, polyphenol-rich
wine lees extracts were shown to modulate FA metabolism and FA profile in zebra fish embryos [49]. To
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the best of our knowledge, this is the first study investigating the potential effects of RV on endogenous
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Figure 1. Molecular pathways of the hepatic endogenous fatty acid synthesis in the endoplasmic 
reticulum and peroxisomes and putative effects of resveratrol (RV) on the expression level and 
activity of involved enzymes and transcription factors. Alpha-linolenic acid (ALA) is converted to 
eicosapentaenoic acid (EPA) and further to 24:6n-3 via elongation and desaturation (∆6-desaturase 
(∆6-D) and ∆5-desaturase (∆5-D)) steps [26]. The partial β-oxidation to form docosahexaenoic acid 
(DHA) takes place in peroxisomes. RV possibly affects ∆6-D and ∆5-D activity, or interacts with ∆6-D 
via transcriptional control of gene expression [48]. Further, RV putatively enhances the peroxisome 
proliferator-activated receptor α (PPARα) gene expression [46,47]. PPARα might induce the 
expression of target genes, for example carnitine palmitoyl transferase 1 (CPT1), sterol regulatory 
element binding protein 1 (SREBP-1) and acyl-CoA oxidase 1 (acox1) [37,38], putatively increasing 
mitochondrial β-oxidation (CPT1), peroxisomal β-oxidation (acox1) and ∆6-D gene expression 
(SREBP-1). Graph made according to Sargent et al. [26] and Burdge [28] and modified according to 
results from previous studies [37,38,46–48] and own data. 
To investigate how the phytochemical RV may affect n-3 LC-PUFA synthesis, feeding 
experiments with rainbow trout were conducted. Experimental diets with RV supplementation and 
differing fish oil inclusion levels and thus, varying dietary LC-PUFA contents were used. The 
resulting FA composition of liver tissue and whole body homogenates, the hepatic mRNA steady 
state levels of ∆6-D, PPARα, CPT1a and CPT1c and hepatic protein levels of ∆6-D were determined.  
2. Results 
2.1. Resveratrol Impairs Body Weight Gain in Rainbow Trout 
At the end of the feeding trial, the mean body weight (FBW) of trout fed the un-supplemented 
basal diets (F4, F2, F0) was significantly higher compared to animals fed diets supplemented with 
RV (F4 + RV, F2 + RV and F0 + RV; Table 1, p < 0.05 indicated by letters). The daily feed intake (DFI) 
was significantly (p < 0.05) reduced in trout fed the RV-supplemented diets compared to 
un-supplemented control diets. The hepatosomatic index (HSI) varied between 1.28 ± 0.30% (F2 + 
RV) and 1.52 ± 0.40% (F4) and did not significantly differ among groups.  
  
Figure 1. Molecular pathways of the hepatic endogenous fatty acid synthesis in the endoplas ic
reticulum and peroxisomes and putative effects of resveratrol (RV) on the expression level and
activity of involved enzymes and transcription factors. Alpha-linolenic acid ( LA) is converted
to eicosapentaenoic acid (EPA) and further to 24:6n-3 via elongation and desaturation (∆6-desaturase
(∆6-D) and ∆5-desaturase (∆5-D)) steps [26]. The partial β-oxidation to form docosahexaenoic acid
(DHA) takes place in peroxiso es. RV possibly affects ∆6-D and ∆5-D activity, or interacts with ∆6-D
via transcriptional control of gene expression [48]. Further, RV putatively enhances the peroxisome
proliferator-activated receptor α (PPARα) gene expression [46,47]. PPARαmight induce the expression
of target genes, for example carnitine palmitoyl transferase 1 (CPT1), sterol regulatory element binding
protein 1 (SREBP-1) and acyl-CoA oxidase 1 (acox1) [37,38], putatively increasing mitochondrial
β-oxidation (CPT1), peroxisomal β-oxidation (acox1) and ∆6-D gene expression (SREBP-1). Graph
made according to Sargent et al. [26] and Burdge [28] and modified according to results from previous
studies [37,38,46–48] and own data.
To investigate how the phytochemical RV may affect n-3 LC-PUFA synthesis, feeding experime ts
with rainbow trout were cond cted. Experimental diets with RV supplementation and differing fish oil
inclusion levels and thus, varying dietary LC-PUFA conten s were used. The resul ing FA composition
of liver tissue and whole body homogen tes, the h patic mRNA ste dy s ate l vels of ∆6-D, PPARα,
CPT1a and CPT1c and hepatic protei levels of ∆6-D were determin d.
2. Results
2.1. Resveratrol Impairs Body Weight Gain in Rainbow Trout
At the end of the feeding trial, the mean body weight (FBW) of trout fed the un-supplemented
basal diets (F4, F2, F0) was significantly higher compared to animals fed diets supplemented with RV
(F4 + RV, F2 + RV and F0 + RV; Table 1, p < 0.05 indicated by letters). The daily feed intake (DFI) was
significantly (p < 0.05) reduced in trout fed the RV-supplemented diets compared to un-supplemented
control diets. The hepatosomatic index (HSI) varied between 1.28 ± 0.30% (F2 + RV) and 1.52 ± 0.40%
(F4) and did not significantly differ among groups.
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Table 1. Growth, feed intake (DFI) and hepatosomatic index (HSI) of rainbow trout fed the experimental
diets. F4, F2 and F0 represent results which were obtained from fish fed the basal diets containing 4%,
2% and 0% DM fish oil. Basal diets were provided either in absence or presence of 0.3% DM resveratrol
(+RV) for an 8-week feeding period.
F4 F2 F0 F4 + RV F2 + RV F0 + RV
IBW 1 35.54 ± 0.20 35.34 ± 0.15 35.69 ± 0.42 35.66 ± 0.15 35.81 ± 0.18 35.63 ± 0.50
FBW 2 46.15 ± 1.26 m 46.37 ± 0.18 x 47.27 ± 2.19 a 41.96 ± 0.90 n 41.60 ± 1.15 y 40.57 ± 1.62 b
DFI 3 1.94 ± 0.07 m 1.95 ± 0.06 x 1.90 ± 0.11 a 1.49 ± 0.04 n 1.49 ± 0.07 y 1.36 ± 0.08 b
HSI 4 1.52 ± 0.40 1.49 ± 0.23 1.40 ± 0.16 1.32 ± 0.24 1.28 ± 0.30 1.51 ± 0.34
Values (mean ± SD, IBW, FBW and DFI: n = 3; HSI: n = 5) with different superscript letters within one row
significantly differ with p-values < 0.05 based on ANOVA as described in Materials and methods. Superscript letters
indicate the output of tests based on comparisons of supplement level within one fish oil inclusion group (a, b: F0
diets; x, y: F2 diets; m, n: F4 diets). 1 IBW = Initial body weight [g]; 2 FBW = Final body weight [g]; 3 DFI = Daily
feed intake [% d−1]; 4 HSI = Hepatosomatic index [%] = (liver weight/final body weight) × 100.
2.2. Experimental Diets Affect the Fatty Acid Composition in Whole Body Homogenates of Rainbow Trout
The FA composition of the diets (Table 2) was equally altered in the basal diets as in the
corresponding RV supplemented diets with decreasing fish oil content. In general, monounsaturated
FA (MUFA) content increased with decreasing fish oil content, while saturated FA (SFA) and PUFA
contents decreased. Predominantly, the absolute amounts of EPA + DHA % DM of diet decreased
with decreasing fish oil content from approximately 0.8% DM (F4 diets) to approximately 0.3% DM
(F0 diets). At the same time, the ratio of ALA (18:3n-3) to LA (18:2n-6) remained unaffected (0.32–0.38)
in all diets (Table 2).
Table 2. Fatty acid composition (in % of total fatty acid methyl esters (FAMEs) and in % DM of diet)
of the experimental diets. F4, F2 and F0 are basal diets containing 4%, 2% and 0% DM fish oil. +RV
indicates supplementation of basal diets with 0.3% DM resveratrol. The standard used for identification
of individual FAMEs consisted of all 11 FAMEs shown here.
[% of FAMEs] F4 F2 F0 F4 + RV F2 + RV F0 + RV
14:0 1.79 1.04 0.70 1.77 1.04 0.35
16:0 11.24 9.75 9.76 11.22 9.74 8.89
18:0 3.58 3.18 3.17 3.55 3.11 2.95
Σ SFA a 16.60 13.97 13.64 16.54 13.90 12.20
16:1 1.72 1.09 0.83 1.73 1.08 0.52
18:1n-9c 33.46 40.03 42.00 33.38 39.67 45.18
18:1n-7c 2.65 2.92 3.14 2.68 2.99 3.21
Σ MUFA b 37.83 44.04 45.95 37.79 43.74 48.91
18:2n-6c 28.83 28.26 27.90 28.87 28.61 27.79
18:3n-3 10.95 10.11 9.29 11.00 10.07 8.93
20:5n-3 2.28 1.44 1.20 2.35 1.40 0.68
22:5n-3 0.49 0.18 0.27 0.32 0.33 0.21
22:6n-3 3.02 2.00 1.80 3.12 1.96 1.27
Σ PUFA c 45.57 41.99 40.42 45.67 42.37 38.89
Σ EPA + DHA d 5.30 3.43 2.35 5.47 3.36 1.96
EPA/DHA 0.75 0.72 0.61 0.75 0.72 0.54
18:3n-3/18:2n-6 0.38 0.36 0.33 0.38 0.35 0.32
Σ EPA + DHA % DM e 0.74 0.56 0.34 0.91 0.56 0.26
a ∑ SFA is the sum of saturated fatty acids; b ∑ MUFA is the sum of monounsaturated fatty acids; c ∑ PUFA is the
sum of n-3 and n-6 polyunsaturated fatty acids; d ∑ EPA + DHA is the sum of eicosapentaenoic acid (20:5n-3) and
docosahexaenoic acid (22:6n-3); e Determination of EPA + DHA % DM of diet was done using the internal standard
13:0 methyl ester and amount of lipid measured in the diet (Table 5).
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The FA composition of the whole body homogenates of rainbow trout was not modified following
a reduction of fish oil content while increasing the vegetable oil content in the basal diets (F4, F2 and
F0; Table 3). Nevertheless, significant increases of EPA and DHA concentrations and simultaneous
significant decreases of 18:2n-6 (LA) and 18:3n-3 (ALA) levels were only detected in whole fish
homogenates when trout were fed the RV-supplemented diets (+RV; Table 3, p < 0.05 indicated by
capital letters A, B). In RV-treated animals, tissue EPA + DHA levels significantly (p < 0.05) increased
from 21.29± 7.29% (F4 + RV) to 32.63± 0.89% (F2 + RV) and 38.35± 3.38% (F0 + RV). The total amount
of PUFA was also significantly (p < 0.05) increased from 38.41 ± 3.91% (F4 + RV) to 47.60 ± 1.55%
(F0 + RV). The n-3/n-6 ratio was significantly (p < 0.05) increased from 2.34 ± 1.45 in fish fed the diet
F4 + RV to 8.24 ± 2.61 in fish fed the F0 + RV diet.
Table 3. Fatty acid composition (in % of total fatty acid methyl esters (FAMEs)) of whole body
homogenates of rainbow trout before (Initial) and at the end of the feeding trial. F4, F2, and F0
represent results which were obtained from fish fed the basal diets containing 4%, 2% and 0% DM fish
oil. Supplementary designation with +RV indicates that fish were fed the diets supplemented with
0.3% DM resveratrol (+RV). The standard used for identification of individual FAMEs consisted of all
11 FAMEs shown here.
[% of FAMEs] Initial F4 F2 F0 F4 + RV F2 + RV F0 + RV
14:0 4.97 3.67 ± 0.29 3.29 ± 0.49 3.47 ± 0.26 a 3.19 ± 0.32 A 2.47 ± 0.19 A,B 1.73 ± 0.69 b,B
16:0 17.73 19.44 ± 0.84 20.15 ± 1.50 19.26 ± 0.52 18.54 ± 1.62 19.57 ± 0.47 20.16 ± 0.63
18:0 4.31 5.78 ± 0.48 6.26 ± 0.73 5.95 ± 0.47 b 5.73 ± 0.96 B 6.59 ± 0.34 A,B 7.96 ± 0.73 a,A
Σ SFA a 27.01 28.89± 1.05 29.70± 2.09 28.68± 0.73 27.46± 2.71 28.63± 0.65 29.85± 0.71
16:1 5.05 4.18 ± 0.52 3.70 ± 0.32 x 3.75 ± 0.29 a 3.50 ± 0.41 A 2.71 ± 0.13 y,A,B 2.15 ± 0.69 b,B
18:1n-9c 27.25 25.03 ± 0.91 23.94 ± 3.65 25.88 ± 1.77 a 27.46 ± 6.18 20.48 ± 0.53 17.91 ± 1.30 b
18:1n-7c 3.36 3.12 ± 0.02 3.10 ± 0.03 + 3.17 ± 0.11 a 3.17 ± 0.21 A 2.8 ± 0.08 A,+ 2.48 ± 0.25 b,B
Σ MUFA b 35.66 32.33± 1.34 30.74± 3.72 32.80± 2.11 a 34.13± 6.61 A 26.00± 0.61 B 22.55± 2.24 b,B
18:2n-6c 14.11 11.81 ± 1.63 10.31 ± 2.67 11.41 ± 1.13 a 12.50 ± 3.44 A 8.72 ± 0.12 A,B 5.46 ± 1.63 b,B
18:3n-3 3.44 2.28 ± 0.35 1.92 ± 0.47 2.02 ± 0.21 a 2.66 ± 0.73 A 1.46 ± 0.10 B 0.97 ± 0.26 b,B
20:5n-3 4.29 3.91 ± 0.10 4.03 ± 0.63 3.74 ± 0.28 b 3.65 ± 1.13 B 4.68 ± 0.20 A,B 5.54 ± 0.41 a,A
22:5n-3 1.97 2.24 ± 0.05 2.28 ± 0.40 2.11 ± 0.12 + 1.95 ± 0.71 B 2.57 ± 0.04 A,B 2.83 ± 0.21 A,+
22:6n-3 13.53 18.55 ± 2.09 21.02 ± 3.88 + 19.24 ± 2.33 b 17.65 ± 6.16 B 27.95 ± 0.84 A,+ 32.81 ± 3.11 a,A
Σ PUFA c 37.34 38.78± 0.65 39.56± 1.74 y 38.52± 1.39 b 38.41± 3.91 B 45.38± 0.93 x,A 47.60± 1.55 a,A
Σ EPA + DHA d 17.82 22.46 ± 2.19 25.05 ± 4.48 22.98 ± 2.60 b 21.29 ± 7.29 B 32.63 ± 0.89 A 38.35 ± 3.38 a,A
EPA/DHA 0.32 0.21 ± 0.02 0.19 ± 0.01 + 0.20 ± 0.01 ++ 0.21 ± 0.01 A 0.17 ± 0.01 B,+ 0.17 ± 0.01 B,++
Σ n-3/Σ n-6 1.65 2.33 ± 0.45 3.03 ± 1.14 2.42 ± 0.57 b 2.34 ± 1.45 B 4.20 ± 0.07 B 8.24 ± 2.61 a,A
a ∑ SFA is the sum of saturated fatty acids; b ∑ MUFA is the sum of monounsaturated fatty acids; c ∑ PUFA is the
sum of n-3 and n-6 polyunsaturated fatty acids; d ∑ EPA + DHA is the sum of eicosapentaenoic acid (20:5n-3) and
docosahexaenoic acid (22:6n-3). Values (mean ± SD, n = 3, Initial: n = 1) with different superscript letters within
one row significantly differ with p-values < 0.05 based on ANOVA as described in Materials and methods. Tests
are based on comparison of supplement type within one fish oil inclusion level (a, b: F0 diets; x, y: F2 diets) or
comparisons of fish oil inclusion level within +RV supplemented groups (A, B). +/++ within one row indicates a
statistical tendency between similarly marked groups with a p-value < 0.1.
When the FA profiles of rainbow trout that were provided with equal dietary fish oil levels, but
either +RV or no supplementation with RV were compared, significant differences were most apparent
in fish fed the fish oil free diets (F0 and F0 + RV). Concentrations of most FA changed in response to
dietary supplementation with RV when compared to the controls (Table 3, p < 0.05 indicated by letters
a, b and x, y). Most noticeably, DHA levels increased from 19.24 ± 2.33% in the controls (basal diet
F0) to 32.81 ± 3.11% in the RV-treated animals (F0 + RV). Dietary supplementation with RV led to a
significant (p < 0.05) increase in the contents of EPA + DHA, as well as total PUFA in the whole body
homogenates of fish fed F2 + RV and F0 + RV diets. The n-3/n-6 ratio significantly (p < 0.05) increased
from 2.42 ± 0.57 in fish fed the F0 diet to 8.24 ± 2.61 in fish fed the F0 + RV diet. No effect on FA profile
was observed in groups which received the reference diets (F4 and F4 + RV).
2.3. Experimental Diets Affect Lipid Levels and Fatty Acid Composition in Livers of Rainbow Trout
The liver lipid levels (total fat mg/g) of rainbow trout fed the six experimental diets were altered
by the dietary fish oil inclusion level and the dietary supplementation with RV (Table 4). The reduction
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of dietary fish oil from 4% DM to 0% DM led to a significant increase in the liver lipid levels (Table 4,
p < 0.05 indicated by letters M, N). Furthermore, in the RV-treated animals, the liver lipid levels were
significantly increased compared to the control animals (F4 + RV in comparison to F4 and F2 + RV in
comparison to F2, Table 4, p < 0.05 indicated by letters m, n and x, y, respectively).
The dietary treatment only slightly affected the relative FA profile (% FAMEs) in the livers of
rainbow trout. The amount of SFA was decreased in fish fed the F0 + RV diet compared to the basal
F0 diet (p < 0.05 indicated by letters a, b), whereas the MUFA and the PUFA contents did not change
based on dietary treatment. When the liver lipid levels are taken into account, the absolute amounts
of EPA + DHA were significantly increased in fish that were fed the F0 diet compared to F4 (Table 4,
p < 0.05 indicated by letters M, N). In the RV-treated fish, the absolute amounts of EPA, DHA and
EPA + DHA were significantly (p < 0.05) elevated when fish were fed the F2 + RV and the F0 + RV diets
compared to the un-supplemented basal diets. The absolute amounts of EPA + DHA were elevated
from 8.69 ± 1.78 mg/g (F0) to 12.38 ± 2.93 mg/g (F0 + RV, Table 4, p < 0.05 indicated by letters a, b) in
the liver tissues. No effect on FA profile was observed in groups which received the reference diets (F4
and F4 + RV).
Table 4. Total fat (mg/g liver) and fatty acid composition (in % of total fatty acid methyl esters (FAMEs)
and in mg/g liver) of liver tissue of rainbow trout before (Initial) and at the end of the feeding trial. F4,
F2, and F0 represent results which were obtained from fish fed the basal diets containing 4%, 2% and 0%
DM fish oil. Supplementary designation with +RV indicates that fish were fed the diets supplemented
with 0.3% DM resveratrol (+RV). The standard used for identification of individual FAMEs consisted of
all 11 FAMEs shown here.
Initial F4 F2 F0 F4 + RV F2 + RV F0 + RV
Total fat [mg/g] 13.60 16.70 ± 1.56 N,n 21.47 ± 3.10 x 26.80 ± 2.55 M 24.80 ± 1.06 m 30.08 ± 3.11 y 26.70 ± 0.99
FA [% of FAMEs]
14:0 1.63 1.45 ± 0.19 1.24 ± 0.13 1.33 ± 0.15 1.32 ± 0.08 1.4 ± 0.15 1.33 ± 0.11
16:0 20.75 22.80 ± 1.01 24.07 ± 1.35 24.30 ± 1.01 a 23.01 ± 0.6 22.89 ± 2.61 21.28 ± 0.71 b
18:0 6.90 8.14 ± 0.59 8.66 ± 0.58 8.15 ± 0.38 7.74 ± 0.38 7.52 ± 1.48 7.12 ± 0.18
Σ SFA a 29.28 32.39± 1.22 33.96± 1.79 33.78± 1.11 a 32.06± 0.89 31.81± 3.95 29.74± 0.79 b
16:1 2.20 1.64 ± 0.21 1.46 ± 0.25 1.92 ± 0.33 1.56 ± 0.25 1.91 ± 0.53 1.70 ± 0.32
18:1n9c 14.93 18.60 ± 4.28 15.14 ± 1.39 14.68 ± 1.00 14.58 ± 0.78 15.61 ± 1.24 16.40 ± 1.64
18:1n7c 2.37 2.55 ± 0.29 2.36 ± 0.23 2.66 ± 0.46 2.46 ± 0.33 2.72 ± 0.37 2.73 ± 0.29
Σ MUFA b 19.50 22.79± 4.73 18.96± 1.86 19.25± 1.62 18.60± 1.23 20.25± 2.13 20.83± 2.19
18:2n6c 8.17 6.09 ± 0.99 6.05 ± 0.99 5.74 ± 0.27 6.27 ± 0.62 5.73 ± 0.52 6.33 ± 0.35
18:3n3 1.45 0.69 ± 0.24 0.56 ± 0.16 0.47 ± 0.11 0.58 ± 0.08 0.57 ± 0.13 0.57 ± 0.20
20:5n3 4.59 3.90 ± 0.25 3.55 ± 0.37 3.65 ± 0.76 4.43 ± 0.41 4.37 ± 0.81 4.61 ± 0.64
22:5n3 1.87 1.87 ± 0.21 + 1.88 ± 0.18 1.89 ± 0.22 b 2.30 ± 0.23 + 2.22 ± 0.22 2.47 ± 0.19 a
22:6n3 35.13 32.26 ± 4.40 35.03 ± 1.48 35.21 ± 1.18 35.77 ± 0.93 35.06 ± 1.71 35.45 ± 1.89
Σ PUFA c 51.21 44.81± 3.51 47.08± 0.21 46.97± 1.96 49.34± 0.72 47.95± 2.49 49.43± 1.79
Σ EPA + DHA d 39.72 36.16 ± 4.50 38.58 ± 1.43 38.86 ± 1.68 40.20 ± 0.63 39.44 ± 2.46 40.06 ± 1.77
EPA/DHA 0.13 0.12 ± 0.02 0.10 ± 0.01 0.10 ± 0.02 0.12 ± 0.01 0.12 ± 0.02 0.13 ± 0.02
Σ n-3/Σ n-6 5.27 6.54 ± 1.67 6.92 ± 1.31 7.19 ± 0.45 6.92 ± 0.77 7.37 ± 1.03 6.83 ± 0.60
EPA mg/g 0.58 0.72 ± 0.24 + 0.70 ± 0.03 y 0.83 ± 0.28 b,+ 1.02 ± 0.08 1.04 ± 0.39 x 1.29 ± 0.23 a
DHA mg/g 4.44 4.79 ± 1.19 N 7.00 ± 1.18 y 7.86 ± 1.52 b,M 8.25 ± 0.42 10.20 ± 0.68 x 11.08 ± 2.75 a
Σ EPA + DHA
mg/g e 5.02 5.51 ± 1.23
N 7.71 ± 1.20 y 8.69 ± 1.78 b,M 9.27 ± 0.37 11.24 ± 0.78 x 12.38 ± 2.93 a
a ∑ SFA is the sum of saturated fatty acids; b ∑ MUFA is the sum of monounsaturated fatty acids; c ∑ PUFA is
the sum of n-3 and n-6 polyunsaturated fatty acids; d ∑ EPA + DHA is the sum of eicosapentaenoic acid (20:5n-3)
and docosahexaenoic acid (22:6n-3); e Determination of EPA + DHA mg/g liver tissue was done using the internal
standard 13:0 methyl ester and amount of total fat in the liver. Values (mean ± SD, n = 3, Initial: n = 1) with
different superscript letters within one row significantly differ with p-values < 0.05 based on ANOVA as described
in Materials and methods. Tests are based on comparison of supplement type within one fish oil inclusion level (a, b:
F0 diets; x, y: F2 diets; m, n F4 diets) or comparisons of fish oil inclusion level (M, N). + within one row indicates a
statistical tendency between similarly marked groups with a p-value < 0.1.
2.4. Dietary Fish Oil Content Affects Hepatic mRNA Expression Levels
The effect of dietary treatments (fish oil level and supplementation of plant bioactive compound)
on mRNA expression levels of ∆6-D, PPARα, CPT1a and CPT1c were investigated in the rainbow trout
livers (Figure 2).
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The reduction of fish oil content in the diet significantly increased the hepatic mRNA expression
levels of ∆6-D in fish following the eight week feeding period (F4 compared to F2, Figure 2a, p < 0.05
indicated by *). Furthermore, hepatic PPARαmRNA expression levels were modulated by the different
dietary fish oil levels (Figure 2b). Fish fed the F0 and F0 + RV diets displayed significantly (p < 0.05)
lower PPARαmRNA expression levels when compared to fish fed the F2 and F2 + RV diets. This effect
was independent of RV supplementation. Similar results were observed for the PPARα target gene
expression CPT1c (Figure 2d). Hepatic mRNA expression of CPT1c was down-regulated when fish
were fed the F0 diet in comparison to F2. When fish were fed diets supplemented with RV, the mRNA
expression levels of CPT1c were significantly down-regulated in the group fed the F0 + RV diet when
compared to F2 + RV and F4 + RV (Figure 2d, p < 0.05 indicated by *). Expression of CPT1a was neither
influenced by dietary fish oil level nor dietary RV.
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ar i levels of fish oil and resveratrol supplementation for eight weeks. (a) ∆6-desaturase; (b) PPARα;
(c) CPT1a and (d) CPT1c were measured in the liver of fish using qRT-PCR and were normalized to
the housekeeping gene EF1α. Feeding groups F4, F2 and F0 were fed basal diets containing 4%, 2%
and 0% DM fish oil, groups with +RV were fed respective diets supplemented with resveratrol. Boxes
represent values (n = 15) between the 25 and 75 percentiles; whiskers indicate 1.5 SD; the solid line
indicates the median; circles represent values above and below SD. Significant differences (p < 0.05)
were analyzed using multiple contrast tests for relative effects. Tests were based on comparisons of fish
oil inclusion level within one supplement group (indicated by *) or supplement type within one fish oil
inclusion level (no significant differences).
2.5. Resveratrol Affects Hepatic ∆6-Desaturase Protein Levels
Protein levels of ∆6-D were determined in the livers of rainbow trout fed different dietary fish oil
levels and in the presence or absence of the dietary plant bioactive compound RV (Figure 3). Feeding
the RV supplemented diets significantly affected hepatic ∆6-D protein levels in trout. ∆6-D protein
levels were significantly increased in the livers of fish fed a diet completely lacking in fish oil (F0 + RV)
Mar. Drugs 2017, 15, 252 8 of 19
when compared to fish fed the F4 + RV and F2 + RV diets (Figure 3, p < 0.05 indicated by *). The
∆6-D protein levels of fish fed the F0 + RV diet (0.823 ± 0.082 ng/mg protein) were equally high when
compared to fish fed the control diet F4 (0.749 ± 0.145 ng/mg protein). Additionally, ∆6-D protein
levels were significantly increased in the livers of fish fed the F0 + RV diet when compared to their F0
fed counterparts (Figure 3, p < 0.05 indicated by a, b). When dietary fish oil is 4%, RV even decreases
the ∆6-D protein levels (F4 and F4 + RV, Figure 3, p < 0.05 indicated by x, y).
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Figure 3. ∆6-desaturase (∆6-D) protein levels in the livers of rainbow trout following dietary treatment
with varying levels of fish oil and resveratrol supplementation for eight weeks. The ∆6-D levels were
measured using ELISA and were normalized to the total protein level (ng/mg protein). Feeding groups
F4, F2 and F0 were fed basal diets containing 4%, 2% and 0% DM fish oil and groups +RV were fed
respective diets supplemented with resveratrol. The dashed line indicates the initial expression value
(n = 1), bars indicate the final expression values (mean + SD, n = 3). Statistically significant differences
(p < 0.05) were analyzed using multiple contrast tests based on comparisons of fish oil inclusion level
within one supplement group (*) or supplement type within one fish oil inclusion group (a, b: F0 diets;
x, y: F4 diets).
3. Discussion
The discrepancy between (1) the need for constant high quality products with (2) the concurrent
increasing demand for fish meal and fish oil for aquaculture production of fish for human nutrition
accompanied by (3) the shortage of marine resources for fish oil production is a well-known yet
unsolved problem. This study focused on the impact of varying fish oil concentrations in fish diets
(4%, 2% and 0% DM) in the absence or presence of the plant bioactive resveratrol (RV, 0.3% of DM) on
n-3 long-chain PUFA synthesis in rainbow trout. The current study revealed positive effects of dietary
RV on the PUFA content in the livers and the whole body homogenate of rainbow trout, including
underlying molecular mechanisms.
The substitution of fish oil by vegetable oils and the provision of alternative, plant-derived
protein sources in the fish diet is a common practice in salmonid and trout aquaculture. This “policy of
replacement” has often caused alterations in the fatty acid composition in fish tissues [13,15,16,27,50,51]
as dietary FA composition is strongly correlated to the fish tissue FA profile [11,12]. Observations
made during this study only partly agree with previous studies. SFA, MUFA and PUFA contents, as
well as single FA concentrations varied within basal diets, but stayed consistent in the whole body
homogenates of fish independent of diet (Table 3). Emery et al. [52] showed that FA tissue composition
did not necessarily reflect dietary FA composition, which may be related to an active in vivo FA
metabolism. Furthermore, Sissener et al. [53] suggested that it may be too simple to presume that
the body FA profile reflects the dietary FA composition since different FA are diversely incorporated
due to their suitability for functional capacities and energy supply. Moreover, the diet formulation
used in this study was intentionally reduced in dietary EPA and DHA content (EPA + DHA levels
in diets: 0.26–0.91% of DM of diet). In the above-mentioned studies, diets were always formulated
to meet the requirements of EPA and DHA in trout [34]. Comparison of the final and initial PUFA
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contents in fish tissue disclosed a reduction in LA, ALA and EPA concentrations (diets F4, F2 and F0).
Simultaneously, an increase in DPA (22:5n-3) and DHA concentration was prevalent. This led to the
assumption that the generally predominant vegetable based formulation of all diets evenly affected the
n-3 FA synthesis regardless of the dietary fish oil level. Furthermore, trout fed a more vegetable based
diet (F2) had significantly increased mRNA expression levels of ∆6-D compared to F4 fed animals.
This was in accordance with previous studies on rainbow trout and salmonids [11,24,29]. Nutritional
modulation of activity and expression of ∆6-D has also been widely observed in teleost fish [29] and in
rainbow trout the maintenance of specific DHA levels was realized by the adaptation of desaturase
activities [11], especially when the diet lacked these LC-PUFA.
The dietary administration of resveratrol (+RV) resulted in a reduction of the final body weight
(FBW), which was predominantly caused by a lower feed intake (DFI) in these fish (Table 1). Since
fish were fed to apparent satiation, the reduced DFI was an indication for lower appetite and earlier
satiety. This effect was only visible in RV-treated groups and not the groups with reduced dietary
fish oil (F2 and F0). Therefore, this indicates the lower palatability of RV-supplemented diets and no
effect of dietary n-3 LC-PUFA levels in general. The lower palatability of fish diets may be caused by
feed additives and secondary plant compounds as reviewed by Ajiboye et al. [54]. Growth depression
and reduced feed intake as a result of dietary administration of secondary plant compounds has been
described for Chinook salmon and rainbow trout [55].
Nevertheless, the RV-supplementation of the experimental diets F2 and F0 (2% and 0% DM fish
oil) significantly elevated EPA, DPA and DHA contents in trout tissue when compared to feeding with
the respective basal diets. Simultaneously, ALA and LA levels were decreased in fish fed the +RV
supplemented diets. An increase in EPA in the triglyceride fraction of zebra fish embryos in response
to RV-rich wine lees had been reported by Caro et al. [49] and partly supports the findings in this study.
In a study with rainbow trout of similar size (IBW of 34 g) that were fed with diets lacking in fish oil,
the dietary administration of the phytochemicals episesamin and sesamin increased relative tissue
EPA and DHA contents (% FAMEs) to levels that are comparable to this study [38]. In both studies,
the EPA amount was increased to approximately 5.5% FAMEs, and the DHA amount was increased
to approximately 43.8% FAMEs in the study by Trattner et al. [38] and to 32.8% FAMEs in this study.
These results indicate a similar potential of RV in rainbow trout fed diets reduced in fish oil when set
into the context described by the other study.
From a scientific point of view, the FA composition of the liver is of great interest, because
endogenous FA synthesis mainly takes place in the liver [56]. The dietary treatments (fish oil reduction
and supplementation with RV) affected the liver lipid levels and the absolute amounts of EPA and
DHA, whereas relative amounts of the FA remained un-changed. A dietary induced change in liver
lipid levels is common in salmonids [11,23,38,57,58]. More interestingly, in this study, the increase in
the liver lipid levels led to the increase of absolute amounts of EPA and DHA, which are increased
further when dietary RV is given (Table 4). RV led to the elevation of DHA in rat hepatocytes [48],
and polyphenol-rich wine lees elevated DHA in zebra fish embryos [49]. Studies with different model
species or cell cultures prove the ability of polyphenols to interact with the hepatic lipid metabolism
and FA synthesis. For example, an episesamin/sesamin mixture led to elevated DHA amounts in
salmon hepatocytes [38], and provinol modified the quantity of liver FA in rats [59]. In general, the
FA compositions of the liver and the whole body homogenate of rainbow trout did not represent the
dietary FA composition, but showed clear influence of RV.
Furthermore, the RV-mediated elevation of DHA in the rat hepatocytes, was ascribed to increased
elongase and desaturase activities of ∆5-D and ∆6-D [48]. In accordance with these findings, the ∆6-D
protein level significantly increased in the livers of fish fed the F0 + RV diet compared to F0, F4 +
RV and F2 + RV fed animals (Figure 3). Overall, this indicates that a RV-dependent enhancement of
desaturation activity when dietary fish oil content is low, is apparent in the increased abundance of the
∆6-D enzyme. The hepatic ∆6-D protein levels were elevated in vivo by dietary RV in the F0 + RV fed
fish to a level equal to the untreated controls (diet F4, Figure 3). The RV-mediated increase of the ∆6-D
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protein level at 0% dietary fish oil, but decrease of the ∆6-D protein level at 4% dietary fish oil can be
explained by a negative feedback. When dietary EPA and DHA is sufficient (in this study 0.74–0.91%
DM), the further synthesis of EPA and DHA seems to be stopped by RV. Only when the dietary EPA
and DHA levels are limited (in this study 0.26–0.56% DM), the FA synthesis is enhanced by RV. This
indicates the effect of RV on the key enzyme of FA bioconversion that finds expression in elevation of
the enzyme itself, as well as EPA and DHA levels in the livers and the whole body homogenate of
trout, when dietary n-3 LC-PUFA are insufficient to meet the requirements, and can be regarded as a
qualitatively important output.
In contrast, the ∆6-D mRNA expression levels were not increased by RV. The phenomenon
of a lack of correlation between ∆6-D mRNA and protein levels was also described by Schiller
Vestergren et al. [24] and Emery et al. [52]. Generally, mRNA expression is very sensitive and rapidly
responds to dietary modifications [37]. Certain phytochemicals, e.g., sesamin and genistein exhibited
a time-dependent activation of PPARα and CPT1 mRNA expression in vitro [37,38]. Thus, in this
study, the enhancement of ∆6-D transcription was possibly not detectable in the liver samples taken
on the second day after the last feeding. Furthermore, post-transcriptional modifications could also
lead to increased mRNA stability [60], resulting in elevated protein levels independent of changes
to mRNA levels. The bioavailability of the phytochemical RV was considered to be rather low [61]
as RV is quickly metabolized, conjugated (by glucuronidation and sulfation [62]), excreted and thus
not necessarily available in the tissues over a longer period of time [63]. Our results suggest that
though there might be low availability of RV, the phytochemical is bioactive and exhibits effects on the
fatty acid profile even at low concentrations. Additionally, RV might not only elevate LC-PUFA levels
by modifying long chain PUFA conversion on a molecular level, but also through the protection of
polyunsaturated fatty acids from oxidation via cell signaling. There is a consistent body of evidence
for the antioxidant properties of RV [64,65], especially highlighted in a study focusing on the effect of
wine polyphenols in human nutrition [66]. Antioxidant activity could be mediated by the induction
of endogenous antioxidant defense mechanisms that are partly under the control of the transcription
factor Nrf2 in humans and mice [67]. Wang et al. [68] also recently showed that RV induced the Nrf2
target gene glutathione peroxidase 4 in laboratory rodents, thereby protecting against oxidative stress.
Dietary administration of RV did not significantly modify hepatic PPARα mRNA expression
levels (Figure 2b). PPARα is a transcription factor which is involved in the regulation of the expression
of numerous target genes involved in FA bioconversion and was modified by RV in vitro and in vivo in
mice [46,47]. Thus, aside from PPARαmRNA quantification, the mRNA expression levels of selected
target genes should also be considered. Administration of RV did not change the hepatic CPT1a and
CPT1c mRNA expression. Both CPT1a and CPT1c are located in the mitochondria and involved in
regulating the rate of PUFA β-oxidation [38,69]. The results presented in this study indicated a general
regulation of mRNA expression of PPARα, CPT1a and CPT1c by dietary fish oil level regardless of
dietary RV. These findings are supported by a study in zebra fish embryos where polyphenol and RV
rich wine lees failed to modulate PPAR expression [49]. Furthermore, findings by Vauzour et al. [70]
indicated that anthocyanidins may not affect FA composition or modify molecular mechanisms of
n-3 FA bioconversion. The mechanism of how RV possibly interacts with transcription factors or
genes exhibiting a PPAR binding site is yet to be fully understood [71]. Furthermore, RV presumably
interacts via mechanisms not investigated in this study. It is well known that RV not only interacts
with the FA synthesis, but the hepatic lipid metabolism in general [48,72,73]. Especially the sirtuin
mediated pathway in the livers of different model species is greatly affected by RV (for example, mice
and humans [73], and zebra fish [74]).
Whether RV activates or inhibits distinct signal transduction pathways seems to mainly depend on
the dose which is applied in vitro and in vivo. Many phytochemicals and dietary supplements exhibit
dose-dependent effects for example, trans-ε-viniferin, cis-viniferin and gnetin H show dose-dependent
cytotoxicity against mouse cancer cell lines in vitro [75]. Additionally, doses of 10 µM genistein,
daidzein, and glycitein inhibited estrogen metabolism in primary liver cell culture from Atlantic
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salmon, lake trout and rainbow trout, whereas lower concentrations had no effect compared to the
controls [76]. Dietary vitamin E supplementation also showed a dose-dependent mode of action
and prevented tissues from lipid oxidation when administered at doses above 100 mg/kg to red sea
bream [77] and salmon [78]. In this study, RV was administered at doses of 3 g/kg, which represented
the upper margin of previously applied concentrations in fish [79–82]. The described effects may help
to understand the lack of effects on the expression of certain genes (PPARα, CPT1a and CPT1c), but
increased protein abundance of ∆6-D and elevated PUFA contents. Hypothetically, the administered
dose of 3 g/kg (RV) might possibly exhibit only minor effects on the level of gene expression, but
over the duration of the eight week trial led to increased amounts of the key enzyme in the LC-PUFA
synthesis on the protein level. At the same time, protection of LC-PUFAs from oxidation possibly via
the induction of endogenous antioxidant enzymes elevated their relative amounts.
The main aim of this study was a mechanistic approach to investigate how the phytochemical
RV may affect n-3 LC-PUFA synthesis. In rainbow trout, it seems that RV generally shows a great
impact on FA synthesis, regardless of the actual bioavailability. It seems to be the case that once RV
reaches the liver of rainbow trout, it interacts with the key enzyme of FA synthesis, ∆6-D. Whether
this interaction is directly or via transcriptional control, cannot be fully explained with the results
obtained in this study. No effect of RV on the mRNA expression of ∆6-D, PPARα, CPT1a, and CPT1c
could be detected with the methods applied. Nevertheless, the elevated amounts of ∆6-D protein in
the livers of fish fed diets with insufficient amounts of EPA and DHA and supplemented with RV
are in accordance with increased absolute amounts of hepatic EPA and DHA. Furthermore, also the
FA profile of the whole body homogenate of these fish shows elevated amounts of EPA and DHA.
Based on literature data and own observations, the processes behind RV mediated activation of the
FA synthesis are most likely via transcriptional control of ∆6-D and ∆5-D (Figure 1) [48,49]. The
protection of FA from oxidation through RV as a chelator of copper and free-radical scavenger [64] or
by interacting with the transcription factor Nrf2 [67,68] most likely adds to the effects of RV on ∆6-D.
However, it should always be taken into consideration, that RV also interacts with other molecules and
pathways (for example uptake of the FA into liver tissue [63], uptake of FA into cell organelles (e.g.,
acox1 [47]), the interaction with the hepatic sirtuin pathway [73,74], or modification of the biochemical
pathways affecting adipogenesis in human adipocytes [72]) that can have indirect effects on the hepatic
FA synthesis pathway. Thus, the observed effects of RV on rainbow trout in this study, are the result
of many different interactions of RV on a molecular and physiological level, leading to the observed
output of elevated EPA and DHA tissue levels.
Taken together, the presented data demonstrate an RV-mediated elevation of PUFAs that can
putatively be ascribed to an elevation of hepatic ∆6-D protein levels and to the potential antioxidant
properties of RV. However, the dietary administration of RV resulted in reduced feed intake in rainbow
trout, which may be related to a lower palatability and warrants further research. Nevertheless, RV
seems to be a promising dietary supplement that has the ability to increase LC-PUFA levels in farmed
rainbow trout fed diets low in fish oil, potentially leading to enhanced fatty acid quality in aquaculture
products. Further research should be conducted in other fish species to address the question of what
extent RV may affect fatty acid profiles.
4. Materials and Methods
4.1. Experimental Diets and Housing Conditions of Rainbow Trout
Six different experimental diets (isonitrogenous and isoenergetic) were formulated on dry matter
(DM) basis as shown in Table 5. All diets contained 10% of fish meal and consisted of equal amounts
of mainly alternative plant protein sources (pea protein isolate, wheat gluten and rapeseed concentrate
amongst others; Table 5). The experimental diets varied in the oil fraction, with decreasing fish oil
contents (F4: 4%, F2: 2% and F0: 0% DM) and increasing vegetable oil contents (F4: 6.6%, F2: 8.6%
and F0: 10.6% DM). Diet F4 served as an overall reference diet and accordingly as the control. Diet
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F2 contained half the amount of fish oil of diet F4 (50% substitution with plant oils) and was set
at the requirement level of EPA + DHA in trout (0.4–0.5% DM of the diet [34]). Diet F0 completely
lacked fish oil (100% substitution with plant oils) and served as the reference for a diet below the
minimum requirement of EPA + DHA in rainbow trout. Fatty acid profiles and absolute amounts
of EPA + DHA % DM of experimental diets are presented in Table 2. The three above-mentioned
diets were referred to as basal diets (F4, F2, F0) and served as controls for similarly composited, but
additionally with resveratrol (RV; trans-3,4′,5-trihydroxy stilbene, purity min. 98%, Chemos GmbH
& Co. KG, Regenstauf, Germany) supplemented diets. Diets F4 + RV, F2 + RV and F0 + RV were
supplemented with RV (0.3% DM, Table 5). The amino acid (AA) content of each diet was calculated
based on the AA contents of single ingredients. All diets were formulated to meet the requirements for
AA content in rainbow trout feed according to Rodehutscord et al. [83] and NRC [34].
Table 5. Ingredients and nutrient composition (in % of dry matter (DM)) of the experimental diets. F4,
F2 and F0 are basal diets containing 4%, 2% and 0% DM fish oil. +RV indicates supplementation of
basal diets with 0.3% DM resveratrol.
Ingredients [% DM] F4 F2 F0 F4 + RV F2 + RV F0 + RV
Fish meal (Clupea sp.) a 10 10 10 10 10 10
Casein b 5.9 5.9 5.9 5.9 5.9 5.9
Rapeseed concentrate c 13 13 13 13 13 13
Pea protein isolate d 13.58 13.58 13.58 13.58 13.58 13.58
Wheat gluten e 17.95 17.95 17.95 17.95 17.95 17.95
Wheat starch e 20 20 20 20 20 20
Fish oil a 4 2 4 2
Linseed oil f 1.50 0.94 0.38 1.50 0.94 0.38
Rapeseed oil g 3.19 6.11 9.04 3.19 6.11 9.04
Sunflower oil g 1.91 1.55 1.18 1.91 1.55 1.18
Vitamin mineral premix h 0.5 0.5 0.5 0.5 0.5 0.5
Lysine i 0.7 0.7 0.7 0.7 0.7 0.7
Dicalcium-phosphate j 1 1 1 1 1 1
Inert filler k 6.77 6.77 6.77 6.77 6.77 6.77
Resveratrol (RV) l 0.3 0.3 0.3
Nutrient composition [% DM]
Dry matter (in % of diet) 93.2 93.1 93.2 93.3 92.8 91.7
Crude protein 50.1 50.3 50.2 50.0 50.3 50.8
Crude lipid 14.9 15.1 15.1 15.0 15.0 15.0
Crude ash 6.4 6.4 6.4 6.4 6.4 6.2
Total KOH m 28.6 28.2 28.4 28.6 28.3 28.0
Gross energy [MJ kg−1 DM] 22.72 22.72 22.70 22.75 22.75 22.93
a Vereinigte Fischmehlwerke Cuxhaven GmbH & Co. KG, Cuxhaven, Germany; b Molkerei MEGGLE Wasserburg
GmbH & Co. KG, Wasserburg, Germany; c BioExx Speciality Proteins LTD, Toronto, ON, Canada; d Emsland-Stärke
GmbH, Emlichheim, Germany; e KRÖNER STÄRKE GmbH, Ibbenbüren, Germany; f Makana Produktion und
Vertrieb GmbH, Offenbach a.d. Queich, Germany; g Different food stores, Büsum, Germany; h Emsland-Aller
Aqua GmbH, Golßen, Germany; i Biolys, Evonik Industries AG, Essen, Germany; j Lehmann & Voss & Co (LuV),
Hamburg, Germany; k Carboxy-methyl-cellulose (CMC), Mikro-Technik GmbH & Co. KG, Bürgstadt/Main,
Germany; l CHEMOS GmbH & Co. KG, Regenstauf, Germany; m Total KOH: total carbohydrates = 1000 − (crude
protein + crude fat + crude ash).
A feeding trial with a total of 486 juvenile rainbow trout (Fischzucht Kortmann GbR,
Hohenweststedt, Germany) was conducted at the facilities of the Gesellschaft für Marine Aquakultur
(GMA) mbH in Büsum, Germany. All experiments were carried out according to the EU Directive
2010/63/EU for animal experiments and approved by the Ministry of Energy, Agriculture, the
Environment, Nature and Digitalization (MELUND), Kiel, Germany (approved on 15 October 2014;
project number: V244-7224.121.9-34). Trout were allowed to adapt to housing conditions prior to
the experiment in a recirculating aquaculture system (7.6 m3, turnover rate 4 times h−1, moving
bed biofilter and additional bead filter (PolyGeyser, Model DF-6, Aquaculture Systems Technologies,
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L.L.C., New Orleans, LA, USA), UV-light disinfection). Light regime was set at 14:10 h light:dark cycle
during adaption and experimental treatment periods. Water quality parameters were determined
daily and maintained in a suitable range for rainbow trout (7.93 pH, 15.1 ± 0.4 ◦C, 9.4 ± 0.3 mg/L O2,
0.2 ± 0.1 mg/L NH4, 6.9 ± 3.4 mg/L NO2 (Microquant test kit for NH4 and NO2, Merck, Darmstadt,
Germany), 2.3 ± 0.7h PSU). Prior to experimental treatment, rainbow trout (mean body weight
36.35 ± 0.03 g) were randomized in six different groups in triplicate, each group with 27 individuals,
and maintained in 18 tanks (150 L) of the experimental system. During the experimental period of
eight weeks, fish were fed manually twice per day (8:30 a.m. and 4:30 p.m.) until apparent satiation.
4.2. Sampling
Samples were collected before the onset of the experimental period (day 0) and at the end of the
experiment (day 58). For initial sampling at day 0, five individuals were sacrificed (pooled sample) and
stored at −20 ◦C for determination of whole body fatty acid composition. In addition, five individuals
were sacrificed for collection of liver samples. For mRNA quantification via qRT-PCR, one part of
the liver tissue was preserved in RNALater (Sigma-Aldrich, Taufkirchen, Germany) and stored at
−20 ◦C. For measurements of the protein levels via ELISA, a second part of the liver tissue was
immediately shock-frozen and stored at −80 ◦C. For the determination of the liver lipid levels and
the liver fatty acid composition, the remaining liver parts of five individuals were pooled into one
sample and immediately stored at −80 ◦C. At the end of the feeding trial at day 58, corresponding
samples for the determination of mRNA and protein levels were taken from five individuals per tank.
Additionally, five individuals per tank were sacrificed (pooled samples) for analysis of whole body
fatty acid composition.
4.3. Lipid Extraction and Measurement of Fatty Acids
Extraction of total lipids and measurement of fatty acid methyl esters (FAMEs) was performed
using a Gas Chromatograph with Flame Ionization Detector (GC-FID).
In brief, total lipids were extracted from liver samples according to Folch et al. [84]. Methylation
of fatty acids and extraction of methylated FAMEs was conducted with the help of the Folch reagent
(chloroform:methanol 2:1). Samples were neutralized using potassium hydroxide (0.1 M) and FAMEs
were isolated by the addition of the Folch reagent and subsequent centrifugation for 10 min at 2000× g.
The organic phase was collected and a second extraction with potassium hydroxide and the Folch
reagent was performed, followed by centrifugation (5 min at 2000× g) and drying of samples under a
N2 flux. Re-dissolved FAME samples were injected into a 7820A Agilent gas chromatograph (Agilent
Technologies, Santa Clara, CA, USA) equipped with an Agilent HP-88 fused silica capillary column
(60 m × 250 µm × 0.2 µm, Agilent Technologies) and helium (1.2 mL/min) as the carrier gas. The
following temperature protocol was applied: initial temperature 125 ◦C, ramp 8 ◦C/min to 145 ◦C
(26 min), ramp 2 ◦C/min to 220 ◦C (5 min). Chromatograms were recorded and analyzed using
EZChrom Elite software (Agilent Technologies). FAME standards (11 FAMEs, see Table 2) were used
to identify retention times of individual FAMEs. Fatty acid composition was calculated as a percentage
of single FAME relative to total FAMEs. FAs as % DM of diet or mg/g tissue were calculated using
13:0 methyl ester as the internal standard.
4.4. mRNA Extraction and qRT-PCR
Total mRNA was extracted from the trout liver samples using the Innuprep RNA Mini Kit
(Analytik Jena, Jena, Germany) according to the manufacturer’s protocol. Tissue was homogenized in
a TissueLyser II (Qiagen, Hilden, Germany) prior to RNA isolation. RNA concentration and purity
were determined via NanoDrop measurements (NanoDrop2000c; ThermoScientific, Waltham, MA,
USA) at 260, 280 and 230 nm absorbance. qRT-PCR was performed with a SensiFast SYBR No-ROX
One-Step Kit (Bioline, London, UK) on a Rotor-Gene 6000 real-time PCR cycler (Corbett/Qiagen).
Primers used and appropriate annealing temperatures are listed in Table 6. Transcript expression was
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absolutely quantified by calculating the input copy number using a standard curve. Subsequently,
respective target mRNA expression levels of ∆6-D, PPARα, CPT1a and CPT1c were normalized to the
mRNA expression level of the housekeeping gene elongation factor 1 α (EF1α). Data are shown as
relative mRNA expression levels of respective target genes normalized to their internal control (EF1α)
following absolute quantification (Figure 2).
Table 6. Primer sequences for hepatic mRNA measurements via qRT-PCR. Forward and reverse
primers as well as their specific annealing temperatures used for qRT-PCR measurements of mRNA
levels in total RNA samples extracted from rainbow trout liver.
Primer Sequence 5′→ 3′ Annealing Temperature (◦C)
∆6-D a,* forward GCTGGAGARGATGCCACGGA 61
∆6-D a,* reverse TGCCAGCTCTCCAATCAGCA 61
EF1α b,* forward ACAAGCCCCTYCGTCTGCC 61
EF1α b,* reverse GCATCTCCACAGACTTSACCTCAG 61
PPARα c,§ forward CTGGAGCTGGATGACAGTGA 55
PPARα c,§ reverse GGCAAGTTTTTGCAGCAGAT 55
CPT1a d,§ forward TCGATTTTCAAGGGTCTTCG 55
CPT1a d,§ reverse CACAACGATCAGCAAACTGG 55
CPT1c d,§ forward CGCTTCAAGAATGGGGTGAT 59
CPT1c d,§ reverse CAACCACCTGCTGTTTCTCA 59
a ∆6-D: ∆6-desaturase; b EF1α: Elongation factor 1 α; c PPARα: Peroxisome proliferator-activated receptor α;
d CPT1: Carnitine palmitoyl transferase 1; * Geay et al. (2012); § Kolditz et al. (2008).
4.5. Enzyme-Linked Immunosorbent Assay (ELISA)
Determination of ∆6-desaturase (∆6-D) protein levels was performed in liver tissue samples
from rainbow trout using a Fish Fatty Acid Desaturase 2 ELISA Kit (MBS066226, MyBiosource Inc.,
San Diego, CA, USA; purchased from Biozol, Eching, Germany) according to the manufacturer’s
instructions. In brief, tissue samples were weighted on dry ice and lysed in phosphate buffered saline
using a TissueLyser II (Qiagen, Hilden, Germany). Following centrifugation, supernatants were applied
to the Microelisa multiwall plate provided by the ∆6-D Kit. Samples were incubated with a HRP
(horseradish peroxidase)-conjugate reagent followed by several washing steps. Protein concentration
was quantified following HRP-mediated color reaction (consecutive application of Chromogen A, B
and Stop solutions) by absorbance measurements at 450 nm using a Labsystems iEMS MF multiplate
reader (MTX Lab Systems, Bradenton, FL, USA purchased from Thermo Fisher Scientific, Darmstadt,
Germany). ∆6-D protein concentration was calculated using a standard curve. ∆6-D concentrations
were normalized to total protein concentrations, which were evaluated via the Pierce bicinchoninic
acid (BCA) kit (Thermo Fisher Scientific) according to the manufacturer’s protocol, respectively.
4.6. Statistical Analysis
All statistical analyses were performed using R (version 3.1.3) with an RStudio interface. The
packages gdata, multcomp, gplots, nparcomp, nlme, and piecewiseSEM were used for graphical and
statistical analysis.
For FA composition, liver lipid levels, IBW, FBW, DFI, HSI and ∆6-D protein levels data evaluation
started with the definition of an appropriate linear model. The data were proven to be normally
distributed and homoscedastic based on a graphical residual analysis. The statistical model included
the level of fish oil content (F4, F2, F0) and supplement (None, RV), as well as their interaction term.
Based on this model, an analysis of variances (ANOVA) was conducted, followed by multiple contrast
tests [85,86] to compare several levels of influencing factors, respectively.
For mRNA expression levels, the data evaluation was initiated with the definition of an
appropriate mixed model [87,88] with fish oil content (F4, F2, F0), supplement type (None, RV) and
their interaction term as fixed factors, and fish tank as random factor. A residual analysis revealed the
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data to be non-normally distributed. Multiple contrast tests for relative effects [86,89] were conducted
to compare several levels of influencing factors, respectively.
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